+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 0Years - 75Years
All Genders
ID06412497

Phase II Study of Reduced Intensity Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide for Severe Aplastic Anemia and Related Bone Marrow Failure Disorders

Led by Masonic Cancer Center, University of Minnesota · Updated on 2026-06-03

60

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a phase II trial of a reduced intensity conditioned allogeneic hematopoietic cell transplant HCT using post-transplant cyclophosphamide PTCy for patients with idiopathic severe aplastic anemia SAA, paroxysmal nocturnal hemoglobinuria PNH, acquired pure red cell aplasia aPRCA, or acquired amegakaryocytic thrombocytopenia aAT. The study uses population pharmacokinetic-guided dosing for conditioning and adjusts low dose total body irradiation based on age and presence of myelodysplasia or clonal hematopoiesis. Participants are divided into two groups those 25 years or younger without clonal hematopoiesis, and those aged 25 to 75 years andor with clonal hematopoiesis. Each group receives a conditioning regimen followed by stem cell infusion and graft-versus-host disease GvHD prevention with drugs including rituximab if needed, rabbit ATG, cyclophosphamide, fludarabine, total body irradiation, tacrolimus, and mycophenolate mofetil. The study treatment phase includes conditioning through day 180, followed by supportive care and follow-up lasting two years post-transplant. During the study, participants undergo regular assessments including monitoring for acute and chronic GvHD, blood cell recovery, and survival up to two years after transplant. Treatment adherence and safety are closely tracked, and various outcomes such as incidence of GvHD and failure-free survival are measured at one and two years post-HCT. This comprehensive follow-up helps evaluate the effects and safety of the transplant approach in these blood disorders.

CONDITIONS

Brief Title

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Research Team

M

Meera Srikanthan, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here